Improving Chronic Conditions Through Inexpensive Interventions
National Institutes of Health
Classification and identifiers
- Solicitation number
- RFA-AG-27-003
- Assistance listing (CFDA)
- 93.866
Amount
Amount not published by the funder
Who can apply
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
About this opportunity
The National Institute on Aging (NIA) intends to publish a Notice of Funding Opportunity (NOFO) to invite applications to create a national consortium of researchers, clinicians, and electronic health record (EHR) vendors. The consortium will conduct research to evaluate clinical effectiveness impacts of different care approaches on whole-person outcomes and quality metrics. This NOFO is intended to support collaborative research efforts for scaling EHR interventions. The consortium will identify proven primary care interventions for older adults with complex medical issues including multiple chronic conditions—ranging from preventive services and chronic care coordination to deprescribing and goal-setting—then integrate these into interoperable, AI- and machine learning-enhanced platforms...
Related opportunities
- Specialized Center Cooperative Agreements in Aging and/or Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) ResearchNational Institutes of Health
- Resource-Related Research Projects Cooperative Agreements in Aging and/or Alzheimer's Disease (AD) and Alzheimer's Disease-Related Dementias (ADRD) ResearchNational Institutes of Health
- Research Project Cooperative Agreements in Aging and/or Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD) ResearchNational Institutes of Health
- Expanding the Therapeutic Pipeline for Treating and Preventing Alzheimer's Disease and Related Dementias: Preclinical Validation and Drug Discovery for Novel Candidate Targets (U01 Clinical Trial Not Allowed)National Institutes of Health
- Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R01 Clinical Trial Required)National Institutes of HealthCloses Jan 2028
- Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)National Institutes of HealthCloses Nov 2026